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Abstract 
PRMT3 is a type I arginine methyltransferase that catalyzes mono- and asymmetric dimethylation of 
arginine residues of various proteins. The protein has demonstrated through in vitro studies 
functionality in the maturation of ribosomes, a possible role in lipogenesis, and has several implications 
in various diseases. The purpose of this project was to develop and characterize a chemical probe that 
potently and selectively inhibits PRMT3 for further use in cellular and animal studies. SGC707, formerly 
known as UNC3108, is the first chemical probe of PRMT3 and was developed via structure based 
optimization. This potent allosteric inhibitor has been thoroughly characterized in a number of 
biochemical, biophysical, and cellular assays. The methods highlighted in this thesis describe synthesis of 
this chemical probe and characterization of this probe by an isothermal titration calorimetry assay. In 
addition to its high potency (IC50 = 31 ± 2 nM, KD = 53 ± 2 nM), SGC707 is selective for PRMT3 over >250 
protein targets. It engages PRMT3 and potently inhibits its methyltransferase activity in cells. Initial 
pharmacokinetic studies also demonstrated that SGC707 is bioavailable and suitable for animal studies. 
Therefore, SGC707 is an excellent tool to further study the role of PRMT3 in health and disease. 
 
Introduction 
Among a variety of epigenetic writers, histone methyltransferases are a class of proteins that are 
targeted to methylate amine rich amino acid residues, primarily lysine and arginine. Protein arginine 
methyltransferases (PRMTs) catalyze arginine methylation and there are currently nine human PRMTs 
that have been identified to date1,2.  PRMTs are further classified based on the reactions the protein 
catalyzes. Type I PRMTs (PRMT1, PRMT2, PRMT3, PRMT4, PRMT6, and PRMT8) catalyze arginine 
monomethylation and asymmetric dimethylation while PRMT5, a type II PRMT, catalyzes arginine 
monomethylation and symmetric demethylation3,4. PRMT7 is unique as a type III PRMT based on strict 
functionality to only monomethylate arginine residues5. With the exception of PRMT4, PRMTs primarily 
methylate glycine and arginine rich (GAR) motifs in their substrates6,7. This protein class plays a critical 
role in the epigenetic based biological processes, including gene expression, transcriptional regulation, 
signal transduction, protein and RNA subcellular localization, RNA splicing and DNA damage repair3,4,8.  
Since its discovery in 1998, PRMT3 has been shown to catalyze asymmetric dimethylation of GAR motifs 
in the 40S ribosomal protein S2 (rpS2), resulting in the stabilization of rpS2 and proper maturation of the 
80S ribosome9,10. Recent studies have demonstrated an increase in expression and co-localization to 
LXRα in the nucleus of cells treated with palmitic acid, leading to regulation of hepatic lipogenesis11. 
PRMT3 methylates the recombinant mammalian nuclear poly(A)-binding protein (PABPN1) with 
potential implications in oculopharyngeal muscular dystrophy, caused by the polyalanine expansion of 
this protein12,13,14. Elevated levels of PRMT3 expression have been shown in myocardial tissues from 
patients with atherosclerosis, describing a potential association of PRMT3 in related diseases15. In 
addition, PRMT3 has been shown to methylate histone peptide (H4 1-24) in vitro16. Histone H4R3 is 
believed to serve as a modification site associated with increased transcription of a number of genes, 
including those under control of estrogen and androgen receptors17,18. Lastly, the interaction of PRMT3 
with the tumor suppressor DAL 1/4.1B suggests a potential role of PRMT3 in tumor growth and possible 
epigenetic regulation of gene expression19. A key piece missing in the current literature is the ability of 
PRMT3 to methylate histones in vivo. 
The development of a well-characterized chemical probes with high potency and selectivity for robust 
on-target activities for a protein of interest is valuable to elucidate biological function of proteins and to 
test therapeutic hypotheses20. In recent publications, an initial inhibitor of PRMT3 (1-
(benzo[d][1,2,3]thiadiazol-6-yl)-3-(2-cyclohexenylethyl)urea, Compound 1 in Figure 1) was characterized 
with IC₅₀ value of 2.5 μM, highlighting a mechanism to inhibit the protein allosterically21,22. While this 
was a major discovery, the level of potency and a discernable level of activity within cells was not 
sufficient enough for classification as a chemical probe. The purposes of our research was to develop a 
more potent, selective, and, most importantly, cell-active chemical probe. Through continued 
optimization of the left-hand side and right-hand side of this compound, the discovery of a chemical 
probe (SGC707) with an IC₅₀ value of 31 ± 2 nM by scintillation proximity assay (SPA) and 66 nM by LC-
MS detection assay at balanced conditions. 
The role of this thesis is to highlight a small portion of this project that includes chemical synthesis of 
SGC707 and the development of the Isothermal Titration Calorimetry (ITC) assay to test the 
thermodynamic properties of the probe’s interactions with PRMT3. Further validation of the chemical 
probe’s activity was verified through assays performed at SGC in Toronto, and these findings will also be 
summarized. SGC707 is the result of years of work and this thesis captures the period of time during the 
final approval of this chemical probe.  
 
Methods 
Chemical Synthesis- 
Chemistry General Procedures.  Analytical thin-layer chromatography (TLC) was performed employing 
EMD Milipore 210-270 µm 60-F254 silica gel plates. The plates were visualized by exposure to UV light. 
Flash column chromatography was performed on a Teledyne ISCO CombiFlash Rf+ system equipped with 
a variable wavelength UV detector and a fraction collector using RediSep Rf normal phase silica columns. 
HRMS analysis was conducted on an Agilent Technologies G1969A high-resolution API-TOF mass 
spectrometer attached to an Agilent Technologies 1200 HPLC system. Samples were ionized by 
electrospray ionization (ESI) in positive mode. Nuclear Magnetic Resonance (NMR) spectra were 
acquired on a Bruker DRX-600 spectrometer. Chemical shifts are reported in parts per million (ppm, δ) 
scale relative to solvent residual peak (chloroform-d, 1H: 7.26 ppm; 13C: 77.16 ppm; methanol-d4, 1H: 
3.31 ppm; 13C: 49.0 ppm). 1H NMR data are reported as follows: chemical shift, multiplicity (s = singlet, d 
= doublet, t = triplet, q = quartet, p = pentet, m = multiplet, app = apparent), coupling constant, and 
integration.  
     
Ethyl (isoquinolin-6-ylcarbamoyl)glycinate. To a stirring solution of 6-aminoisoquinoline (300 mg, 2.08 
mmol, 1 eq.) in dichloromethane (100 mL) was added ethyl isocyanatoacetate (0.35 mL, 3.12 mmol, 1.5 
eq.) and the resulting mixture was stirred overnight at room temperature. The progress of the reaction 
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was monitored by TLC. After removal of volatiles, the crude mixture was purified by flash column 
chromatography (gradient from 100% dichloromethane to 10% methanol in dichloromethane) to yield 
desired ethylester (460 mg, 81% yield) as pale yellow solid. 1H NMR (600 MHz, Chloroform-d) δ 8.94 (s, 
1H), 8.31 (d, J = 5.8 Hz, 1H), 8.07 (s, 1H), 7.91 (s, 1H), 7.67 (d, J = 8.8 Hz, 1H), 7.35 (d, J = 5.8 Hz, 1H), 7.29 
(d, J = 8.8 Hz, 1H), 6.13 (t, J = 5.6 Hz, 1H), 4.26 (q, J = 7.2 Hz, 2H), 4.13 (d, J = 5.5 Hz, 2H), 1.31 (t, J = 7.1 
Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 172.23, 155.37, 151.47, 142.91, 140.84, 137.05, 128.60, 125.06, 
121.06, 120.34, 112.60, 62.07, 42.21, 14.30. HRMS (m/z) for C14H16N3O3+ [M + H]+ calculated 274.1186 
found 274.1185. 
 
1-(isoquinolin-6-yl)-3-(2-oxo-2-(pyrrolidin-1-yl)ethyl)urea (SGC707). To a stirring solution of ethylester 
(200 mg, 0.731 mmol, 1 eq.) in THF/H2O (10 mL/5 mL) was added LiOH (anhydrous, 35.0 mg, 2.0 eq.) and 
the resulting mixture was stirred overnight at room temperature. The disappearance of starting material 
was monitored by TLC. Crude mixture was then concentrated under reduced pressure and residue was 
re-suspended in dioxane (10 mL), followed by addition of thionyl chloride (0.50 mL, 6.89 mmol, 9.4 eq.) 
and heated to 80 °C for 30 minutes. Resulting crude mixture was again concentrated under reduced 
pressure and re-dissolved in dioxane (10 mL) followed by addition of pyrrolidine (0.30 mL, 3.65 mmol, 
5.0 eq.) and allowed to stir at room temperature overnight. The progress of the reaction was again 
monitored by TLC. The crude product was then purified by flash column chromatography (gradient from 
100% dichloromethane to 10% methanol in dichloromethane) to yield SGC707 (189 mg, 87% overall 
yield after 3 steps) as pale yellow solid. 1H NMR (600 MHz, Methanol-d4) δ 9.03 (s, 1H), 8.29 (d, J = 5.9 
Hz, 1H), 8.10 (d, J = 2.1 Hz, 1H), 7.98 (d, J = 8.9 Hz, 1H), 7.65 (d, J = 6.0 Hz, 1H), 7.59 (dd, J = 8.9, 2.0 Hz, 
1H), 4.06 (s, 2H), 3.53 (t, J = 6.8 Hz, 2H), 3.48 (t, J = 6.9 Hz, 2H), 2.03 (app p, J = 6.8 Hz, 2H), 1.91 (app p, J 
= 6.9 Hz, 2H).13C NMR (151 MHz, Methanol-d4) δ 169.64, 157.55, 152.18, 143.67, 142.90, 138.81, 129.87, 
126.23, 122.27, 121.72, 112.41, 47.19, 46.72, 43.22, 26.94, 25.09. HRMS (m/z) for C16H19N4O2+ [M + H]+ 
calculated 299.1503 found 299.1500. 1H NMR and 13C NMR spectra are located in the Appendix section. 
Protein Purification- 
A DNA plasmid with the PRMT3 DNA insert cloned into the T7 promoter region of the commercial 
pET28a-LIC Vector was obtained from SGC of Toronto. The DNA plasmid was transformed into DH5-
alpha cells and the cultures were plated under kanamycin resistance (50 μg/mL). Several colonies were 
selected and grown in 2 mL LB cultures with 50 μg/mL. The resultant cell cultures were lysed and the 
DNA plasmid was purified via the QIAprep Spin Miniprep Kit. The plasmid was sequenced and verified to 
have an accurately in frame DNA insert.  
The purified PRMT3-pET28a plasmid was transformed into BL21-V2R-pRARE-2 cells. One colony was 
inoculated into 50 mL of LB supplemented with 50 μg/mL kanamycin and 30 μg/mL chloramphenicol and 
incubated with shaking overnight at 37°C. The culture was then inoculated into 4 L of LB supplemented 
with 50 μg/mL kanamycin and 30 μg/mL chloramphenicol and grown to an OD₆₀₀ of about 1. Protein 
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expression was induced by the addition of 0.5 mM isopropyl-1-thio-D-galactopyranoside (IPTG) with 
shaking for 16 hours at 15°C. Cells were then harvested by centrifugation and the pellets were flash 
frozen at -80°C. The cells were then thawed and re-suspended in binding buffer (10 mM Tris, 500 mM 
NaCl, 5 mM imidazole, 5% glycerol, pH 7.5) with protease inhibitors (1 mM benzamidine HCl , 1 mM 
phneylmethanesulphonylfluoride (PMSF)). The thawed cells were lysed via sonication in the presence of 
protease inhibitors at a frequency of 8.5 for three cycles of 10 seconds on and 10 seconds off using a 
Misonix Sonicator 3000. Once the cell lysate was clarified by centrifugation, the supernatant was loaded 
onto a Ni-NTA Superflow column (Qiagen, CAT# 30450) pre-equilibrated with binding buffer. The column 
was washed with 60 CV of wash buffer (10 mM Tris, 100 mM NaCl, 30 mM imidazole, 5% glycerol, pH 
7.5) and the protein was eluted with elution buffer (10 mM Tris, 100 mM NaCl, 250 mM imidazole, 5% 
glycerol, 1 mM EDTA, 1 mM DTT, pH 7.5). Eluted protein fractions were directly loaded onto a size 
exclusion column (Bio-Rad Enrich SEC 650 10 x 300 mm column (780-1650)) and eluted in a modified 
elution buffer (10 mM Tris, 100 mM NaCl, 5% glycerol, 1 mM EDTA, 1 mM DTT, pH 7.5). Accurate protein 
mass (~60 kDa) and purity was verified via SDS-PAGE analysis and Western blot analysis.  
ITC Experiments- 
All ITC measurements were performed at 25 °C using an AutoITC200 microcalorimeter (MicroCal/GE 
Healthcare). The calorimeter cell (volume 200 µL) was loaded with PRMT3 protein in the full salt dialysis 
buffer (100 mM NaCl, 10 mM Tris, 5% glycerol, 1 mM EDTA, 1 mM DTT) at a concentration of 100 µM. 
The syringe was loaded with SGC707 (dissolved in the same buffer) at a concentration of 1 mM. A typical 
injection protocol included a single 0.2 µL first injection followed by twenty-six 5.0 µL injections of the 
compound into the calorimeter cell. The spacing between injections was kept at 180 s and the reference 
power at 8 µcal/sec. A control experiment was performed by titrating SGC707 into buffer under identical 
settings to determine the heat signals that arose from compound dilution; these were subtracted from 
the heat signals of protein–compound interaction. The data were analyzed using Origin for ITC, ver. 7.0, 
software supplied by the manufacturer; and fitted well to a one-site binding model. 
Additional Methods- 
Other in vitro, in vivo, and animal based studies in addition to the synthesis of an inactive control were 
conducted to further demonstrate the capabilities of SGC707. Based on limited involvement in these 
procedures, these methods are more adequately described in the recently approved publication in by 
Kaniskan et al. in Angewandte Chemie23. 
 
Results 
Utilizing the previously published molecule as a template, the first chemical probe of PRMT3 was a 
product of left hand side and right hand side moiety modification. The urea bridge remained the central 
portion of the molecule, effectively binding at the E422 and R396 amino acid residues. The first major 
modification was achieved by switching from a benzothiadiazole left hand moiety to an isoquinoline. 
The isoquinoline group was proven to form a hydrogen bond with the T466 residue of the allosteric 
cavity with a higher affinity. With the left hand side and the urea group in place, much of the continued 
modification focused on optimizing the right hand side of the molecule. The pyrrolidine amide is thought 
to most effectively bind in alpha helix side of the cavity and effectively constrains the ability of the alpha 
helix to form a catalytically competent state. The alpha-helix is a dynamic secondary element that is 
conserved in class I PRMTs, thus it is thought the direct or water mediated interactions with the K392 
residue near this structure increased its potency and contribute to the compound’s activity. The crystal 
structure of the PRMT3-SGC707 confirmed the compound’s activity in the PRMT3 allosteric site. The 
structural changes to the molecule are exhibited in Figure 1 and the interaction within the allosteric site 
is depicted in Figure 2. 
 
Figure 1. The structure-based optimization of the novel allosteric inhibitor of PRMT3 from previous 
publication in Structure21. From compound 1 to SGC707, a near 100 fold increase in potency was 
observed with conservation of the urea group and modification of both left hand and right sides of the 
compound. Inactive control, XY1, is also depicted, with the replacement of the isoquinoline group with a 
napthyl group. 
 
Figure 2: SGC707 interacting with the allosteric binding site of PRMT3. Key sites of hydrogen binding are 
exhibited via T466 and the isoquinoline group, E422 and the nitrogen atoms of the urea group, and R396 
and the carbonyl of the urea group. The right handed side consisting of an amide bound pyrrolidine 
preferentially filled the binding site via hydrophobic interaction. Interaction of SGC707 and the allosteric 
site forces the α-helix out of conformation, leading to an inactivated PRMT3 protein.  
 
To further test the importance of particular moieties in SGC707, several inactive controls were 
proposed. Initially, methyl groups were to be added to the nitrogen atoms of the urea group. Due to 
extensive issues synthesizing and purifying these compounds, removal of the isoquinoline group in favor 
of a naphthyl group was pursued, yielding compound XY1 (Figure 1). XY1 was completely inactive against 
PRMT3 at concentrations as high as 100 μM, confirming the importance of the key hydrogen bond with 
T466. 
Binding of SGC707 was confirmed by isothermal calorimetry (ITC) with a KD value of 53 ± 2 nM (n = 3) 
(Figure 3) and surface plasmon resonance (SPR) with a KD value of 85 ± 1 nM (n = 3) (kon of 1.17 ± 0.05 x 
105 M-1 s-1 and koff of 0.99 ± 0.03 x 10-2 s-1) (Figure 4). SGC707 also exhibited a long residence time, 
demonstrating great improvement over compound 1 (kon = 5.1 ± 0.57 x 104 M-1 s-1 and koff = 0.76 ± 0.09 
s-1)21. SGC707 was also selective for PRMT3 over 31 protein-, DNA-, RNA-methyltrasferases (Figure 5) 
and a broad range of non-epigenetic targets including >250 kinases, G protein coupled receptors 
(GPCRs), ion channels, and transporters. It showed modest inhibition at 10,000 nM for only 6 (5HT2B 
69%, BRSK1 56%, DLK1 60%, MSK2 55%, PKG2 58%, and PRKX 61%) out of >250 targets. In mechanism of 
action studies, SGC707 suggested activity at the allosteric site by displaying a non-competitive inhibition 
pattern with respect to both the cofactor S-(5’-adnosyl)-L-methionine (SAM) and peptide substrate 
(Figure 6). 
 
Figure 3: ITC experiments were performed using purified PRMT3 that was dialyzed overnight in 100 mM 
NaCl buffer, 10 mM Tris, 5% glycerol, 1 mM DTT, 1 mM at pH 7.5. ITC titrations were performed on a 
MicroCal Auto-iTC200 from Malvern at 25 °C by using a single 2 µL first injection followed by 25 of 5.0 
µL- injections of the compound into the calorimeter cell. Data were fitted with a one-binding site model 
using Origin7 software. Experiments were performed in triplicate with a KD value of 53 ± 2 nM. 
 
Figure 4: SPR studies were preformed and full methods are described in Kaniskan U, et al23. The KD value 
of 85 ± 1 nM, kon of 1.17 ± 0.05 x 10⁵ Mˉ¹ sˉ¹ and koff of 0.9953 ± 0.0292 x 10ˉ² sˉ¹ were calculated by 
averaging values obtained from three independent runs. 
 
Figure 5: Other epigenetic drug targets assessed, including 27 other protein methyltransferases, 3 DNA 
methyltransferases and on RNA methyltransferase. Level of protein activity was assessed at 1 (red), 5 
(green), and 20 (purple) μM of SGC707 and no inhibition was observed.  
 
Figure 6: Confirmation of the non-competitive pattern of inhibition for SGC707 with respect to SAM, an 
important cofactor of PRMT, and the peptide substrate, demonstrating the allosteric mode of inhibition. 
Similar patterns were observed by conserving either SAM or peptide at saturation level while varying the 
concentration of the other molecule. In each case, there was no significant variation of the IC₅₀.  
To demonstrate target engagement of SGC707 in cells, an InCELL Hunter Assay was used. The assay 
measures intracellular binding of SGC707 to the methyltransferase domain of PRMT3 in cell lines 
expressing the methyltransferase domain of PRMT3 tagged with a short fragment of β-galactosidase. 
SGC707 stabilized PRMT3 in both HEK293 and A549 cells with EC₅₀ values of 1.3 μM and 1.6 μM 
respectively (Figure 7A). Based on prior evidence of PRMT3 methylating histone peptides, SGC707 
inhibition of PRMT3 catalytic activity on H4R3 asymmetric dimethylation was assessed in cells. 
Methylation of both endogenous H4 and exogenously introduced GFP-tagged H4 was observed by 
overexpressing human Flag-tagged PRMT3. Overexpressed PRMT3 increased the endogenous 
H4R3me2a from the baseline levels and SGC707 was able to reduce this increase (Figure 7B & 7C) with 
an IC₅₀ of 225 nM. The exogenous H4R3 asymmetrical dimethylation was inhibited with an IC₅₀ of 91 nM 
(Figure 7B & 7D). Baseline levels of H4R3me2a were measured via the catalytically dead PRMT3 mutant 
(E335Q). SGC707 at 1 μM was almost as effective at reducing the H4R3me2a levels as the catalytically 
dead PRMT3 mutant E335Q at similar concentrations. Such evidence clearly indicates that SGC707 can 
engage PRMT3 while effectively inhibiting its catalytic activity in cells and that overexpressed PRMT3 can 
methylate histone H4 in cells. 
 
Figure 7: (A) SGC707 concentration-response curves with the PRMT3 InCELL Hunter Assays. HEK293 or 
A549 cell lines expressing the methyltransferase domain of PRMT3 fused to the enhanced ProLabel (ePL) 
β-galactosidase fragment were incubated for 6 hours at 37C with increasing concentrations of SGC707. 
The abundance of the ePL-PRMT3 fusion protein was measured by lysing the cells in the presence of 
chemiluminescent enzyme substrate and the complementary EA β-galactosidase enzyme fragment. RLU, 
relative light units. (B) Western blot analysis of H4R3me2a levels. HEK293 cells were co-transfected with 
FLAG tagged PRMT3 (WT) or its catalytically dead mutant E335Q (Mut) and treated with different 
concentrations of SGC707, as indicated. Total cell lysates were collected 24 h post inhibitor treatment 
and analysed for H4R3me2a levels. The total levels of exogenous and endogenous histone H4 and 
overexpressed PRMT3 were determined with anti-GFP, anti-H4 and anti-FLAG antibodies, respectively. 
(C) Quantitation of SGC707 effect on the endogenous H4R3me2a. (D) Quantitation of SGC707 effect on 
the exogenous H4R3me2a. The graphs represent non-linear fits of H4R3me2a signal intensities 
normalized to intensities of GFP or H4 for exogenous and endogenous H4, respectively and subtracted 
from the baseline signal from mutant PRMT3. The results are Mean ± SEM of three replicates. 
In vivo pharmacokinetic properties of SGC707 were also assessed (Figure 8). Intraperitoneal injection of 
SGC707 at 30 mg/kg yielded decent plasma exposure in CD-1 male mice over 6 hours with a peak plasma 
level of 38,000 nM. The plasma level of SGC707 at 6 hours post injection was 208 nM, more than 2-fold 
higher that its IC₅₀ value in the cellular assay. The dose was well tolerated by the test animals and 
suggest SGC707 is suitable for animal studies in addition to cell based assays. 
 
Figure 8: Plasma exposure of SGC707 in male CD1 mice. Plasma concentrations of SGC707 following a 
single 30 mg/kg IP injection over 6 h. The dashed black line indicates the cellular IC50 of SGC707. 
 
 
Discussion 
SGC707 is a first-in-class PRMT3 chemical probe which is a potent and cell-active allosteric inhibitor of 
PRMT3. Through several assays, it has been demonstrated to be remarkably selective for its PRMT3 
target over 31 other similarly functioning proteins in addition to a wide range of other proteins. Multiple 
cell-based assays have demonstrated SGC707’s ability to potently inhibit PRMT3 methyltransferase 
activity. This is the first ever report suggesting H4 as a target for PRMT3 in cells. There is need for further 
studies to confirm if endogenous PRMT3 plays a major role in H4R3 asymmetric dimethylation. In 
addition, it has yet to be determined if this methylation occurs in the cytoplasm shortly after H4 
translation and loading onto the chaperone complexes. The bioavailability and suitability for animal 
studies allows SGC707 to become a valuable tool for elucidating this potentially significant interactions. 
Epigenetic drug discovery is merely in its infancy, with only a few agents approved by the FDA currently 
and several others in clinical development. HDAC inhibitors are currently on the market, with the most 
recent, belinostat, being approved just last year for the treatment of relapsed or refractory peripheral T-
cell lymphoma24. DNA methyltransferase inhibitors, such as azacitadine and decitabine, have been 
approved for the treatment of myelodysplastic syndromes25,26. With continued research, it has been 
demonstrated that these targets are only a small subset of the entire epigenome, leaving much left to 
be warranted and discovered. The success of these agents have led to the growing interest in chemical 
regulation of chromatin mediated signaling21.  
Through research within the Jian Jin Laboratory alone, SGC707 became the third chemical probe 
discovered to potently inhibit protein methyltransferases. UNC1999 potently inhibits EZH2 and EZH1 
which catalyze the methylation of histone H3 Lysine 27. The overexpression of EZH2 and the 
hypertrimethylation of H3K27 have been implicated in a number of cancers, thus UNC1999 serves as a 
valuable tool to investigate the role of EZH2 and EZH1 in health and disease27. Similarly, UNC0642 was 
found to be a potent selective inhibitor of the lysine methyltransferases G9a and GLP, which catalyze 
mono- and dimethylation of H3 lysine 9 in addition to other non-histone proteins28. All three agents 
exhibited high cellular potency with limited cell toxicity, excellent selectivity and pharmacokinetic 
properties suitable for animal-based studies. The use of SGC707, in addition to UNC1999 and UNC0642, 
in further animal studies will not only further elucidate the utility of these agents as potential 
treatments, but may also uncover many mysteries of the epigenome in the process. 
PRMT3 has many proposed roles in the human cells, as outlined in the introduction of this thesis. The in 
vivo studies have demonstrated a clear role of SGC707 to impact PRMT3 activity at the H4R3 site. In 
addition to more work to fully understand the role of PRMT3-H4R3 interaction, other sites of interest 
should also be considered. These include PRMT3 mediated rpS2 methylation and 80S ribosome 
maturation, PABPN1 methylation in oculopharyngeal muscular dystrophy, and inhibited 
methyltransferase activity via interaction with tumor suppressor DAL-1/4.1B. To further expand upon 
these potential implications of PRMT3, the development of future in vivo studies and animal studies 
could be greatly aided via the use of SGC707. Through collaboration of the multi-faceted resources of 
other laboratories around the world, it is hoped this chemical probe could aid in a great number of 
discoveries associated with PRMT3 in coming years. 
In conclusion, SGC707 is the first in class allosteric inhibitor of PRMT3 and poses great potential in the 
facilitation of further epigenetic research in the protein’s role in health and disease.  
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